Navigation Links
Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism
Date:2/16/2012

EXTON, Pa., Feb. 16, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that data from the pivotal study for their orphan drug Plenadren® (hydrocortisone, modified release tablet) were published in the Journal of Clinical Endocrinology and Metabolism (JCEM), a leading scientific journal for endocrinology. Plenadren was recently granted European Marketing Authorization for treatment of adrenal insufficiency in adults.

The authors described results showing that the once daily dual-release tablet provided a more circadian-based serum cortisol profile, and that reduced body weight, reduced blood pressure, and improved glucose metabolism were observed during once daily treatment, compared to treatment with immediate release hydrocortisone three times per day.  In particular, the authors noted glucose metabolism improved in patients with concomitant diabetes mellitus. In addition, the preference of once daily versus three times per day treatment was assessed to be large or very large by 85 percent of patients at 12 weeks.

Professor Gudmundur Johannsson of the Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden, and primary author of the publication, commented, "These data indicate that patients with Addison's Disease now have an important therapeutic option with once daily Plenadren.  The time-exposure of Plenadren may be important in improving the outcome of patients suffering with adrenal insufficiency." 

Replacement therapy for the treatment of the rare disease adrenal insufficiency has been available for more than 50 years. Oral hydrocortisone is the most widely used replacement therapy for treatment, but no formal studies of its efficacy and safety have been performed in patients suffering from adrenal insufficiency. The JCEM publication entitled, 'Improved Cortisol Exposur
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
(Date:1/14/2014)... PLYMOUTH, Minn. , Jan. 14, 2014   NuAire , a ... come to agreement with Hitachi Koki of ... centrifuges in North America . NuAire will utilize ... and Canada to offer assistance ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... NEW YORK, Nov. 3, 2010 Coronado Biosciences, ... oncology drug development, announced completion of a series ... gross proceeds to the Company of approximately $21.6 ... from these financings for general corporate purposes, including ...
... Nov. 3, 2010 Telik, Inc. (Nasdaq: TELK ... $0.09 per share, for the third quarter ended September 30, ... $0.11 per share, for the comparable period in 2009. ... costs and expenses were $4.7 million, compared with $6.2 million in ...
Cached Medicine Technology:Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update 2Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update 3Telik Announces Third Quarter 2010 Financial Results 2Telik Announces Third Quarter 2010 Financial Results 3
(Date:4/17/2014)... -- The world is less than 40 years away ... for people and governments, according to a top scientist ... first time in human history, food production will be ... land, water and energy," said Dr. Fred Davies, senior ... "Food issues could become as politically destabilizing by 2050 ...
(Date:4/17/2014)... 17, 2014While 94 per cent of Canadians surveyed said ... newborns for a specific number of genetic conditions, only ... participate in screening that would sequence their newborns, genomes.,Most ... in their first day or two of life in ... their heels and tested for about five to 54 ...
(Date:4/17/2014)... Vice-Chancellor, Professor Patrick Johnston, whose work has transformed cancer ... Fellow of the European Academy of Cancer Sciences., The ... advisory body of highly distinguished oncologists and cancer researchers ... by cancer in Europe. , Professor Johnston, whose leadership ... from the bottom of the UK league table to ...
(Date:4/17/2014)... from LSTM have called for more research to ... in children in sub-Saharan Africa. In a paper ... Professor Russell Stothard, working with colleagues in the ... Reserve University, in Cleveland Ohio, University of Cambridge ... research into the joint burden of HIV/AIDS and ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research ... their annual Founders Dinner for their support of TGen,s ... took place March 28 in Scottsdale. , Catherine Ivy, ... Foundation, received TGen,s John S. McCain Leadership Award, named ...
Breaking Medicine News(10 mins):Health News:Food shortages could be most critical world issue by mid-century 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... 2011 Metabolomx, a diagnostic company focused on the ... breath, today announces publication of results from the first ... detect lung cancer and differentiate between types of lung ... the Cleveland Clinic and led by Dr. Peter Mazzone, ...
... patients in a New England Journal of Medicine ... recovered from hip surgery, according to new research co-authored ... findings could immediately change the way such patients are ... strengthen patients weakened by anemia, improving their chances at ...
... been diagnosed with locally-advanced pancreatic cancer in the United ... for these patients whose tumor has grown beyond the ... 20 years, numerous treatment regimens have been evaluated for ... being the current standard approach. However, the median survival ...
... , WEDNESDAY, Dec. 14 (HealthDay News) -- Alcohol ... more of them are using marijuana and don,t believe it,s ... by the U.S. National Institute on Drug Abuse and the ... students in grades eight, 10 and 12 at 400 public ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Dec. 14 ... cholesterol levels, may one day also prove useful in combating ... the Journal of Infectious Diseases finds that patients ... were taking a statin, compared with their peers who weren,t ...
... News) -- In the aftermath of a deadly crash in ... Transportation Safety Board is recommending a nationwide ban on drivers, ... emergencies. According to media reports, the board was meeting ... occurred last year in Gray Summit, Mo. The NTSB ...
Cached Medicine News:Health News:Metabolomx test detects lung cancer from breath 2Health News:Metabolomx test detects lung cancer from breath 3Health News:University of Maryland finds restricting post-surgery blood transfusion is safe for some hip patients 2Health News:University of Maryland finds restricting post-surgery blood transfusion is safe for some hip patients 3Health News:RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer 2Health News:Alcohol Use Down, Pot Use Up Among U.S. Teens 2Health News:Could Statins Help Those Hospitalized With Flu? 2Health News:U.S. Safety Board Urges Nationwide Ban on Drivers' Use of Cellphones 2
This lens gives the appearance of mystery and mayhem behind the blackest of eyes....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Medpor Sphere Inserter. The Inserter is provided as a value added item to Medpor Orbital Implants....
Reusable cannula with .90 mm (20 g) shaft, tapering to .30 mm (30 g). Angled 125 3 mm from tip and flattened for easy insertion into the subretinal space....
Medicine Products: